SIGA Technologies’ Barda Contract Renewal May Be Required To Sustain Recent Momentum

Photo of author
Written By Marcus Reynolds

SIGA Technologies (NASDAQ: SIGA) is a commercial-stage pharmaceutical company specializing in the production and sale of TPOXX, an oral antiviral drug used to treat smallpox disease.

While SIGA has enjoyed profitability and market success, its heavy reliance on government contracts, particularly with the U.S. Biomedical Advanced Research and Development Authority (BARDA), poses significant risks to its future growth and valuation.

Despite recent positive earnings and promising expansion plans, uncertainties surrounding the renewal of its BARDA contract warrant a cautious outlook toward the company as an investment option.

Company Background

Credits: DepositPhotos

SIGA Technologies operates as a profitable pharmaceutical company, primarily selling TPOXX to the U.S. government and international markets. However, its revenue stream is heavily dependent on BARDA contracts, raising concerns about future growth prospects and valuation.

While SIGA has reported strong earnings and pursued expansion initiatives, uncertainties surrounding the renewal of its BARDA contract and potential competition underscore the need for a cautious investment approach, resulting in a rating downgrade.

Investment Overview

SIGA’s core product, TPOXX, has been pivotal to its success, with regulatory approvals from the FDA, European Medicines Agency (EMA), Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA).

The company’s revenue stream predominantly stems from BARDA contracts, supplying TPOXX to the U.S. Strategic National Stockpile.

While SIGA has demonstrated profitability and operational efficiency, its limited product portfolio and heavy reliance on government contracts pose challenges to sustained growth.

SIGA’s BARDA Contracts

Over the past decade, SIGA has generated significant revenue from BARDA contracts, with consistent earnings and impressive margins. However, concerns arise due to its overreliance on these contracts, particularly as revenues from other sources remain limited.

Despite profitability, the lack of diversification and growth opportunities beyond TPOXX highlights potential vulnerabilities in SIGA’s business model.

Renewal Risks and Expansion Plans

SIGA’s recent earnings report showcased positive financial performance and expansion initiatives, including international sales and clinical studies for new indications like post-exposure prophylaxis (PEP) and pediatric applications.

However, uncertainties surrounding the renewal of its BARDA contract raise concerns about future revenue streams and valuation. While SIGA management remains confident in securing a new contract, competition and regulatory dynamics pose risks to its market position and profitability.

Proceed With Caution

Given the uncertainties surrounding SIGA’s BARDA contract renewal and limited growth prospects, investors should proceed with caution. While recent earnings and expansion efforts are encouraging, the company’s heavy reliance on government contracts and potential competitive pressures underscore the need for caution.

Investors should monitor developments closely and adjust their investment strategy accordingly, considering the risks associated with SIGA’s business model and market dynamics.

Government Contract Challenges

Credits: DepositPhotos

SIGA Technologies faces challenges related to its heavy reliance on government contracts, particularly with BARDA, and limited growth opportunities beyond its core product, TPOXX. While recent financial performance and expansion initiatives are promising, uncertainties surrounding contract renewals and competitive pressures warrant a cautious investment approach.

Investors should assess SIGA’s risk profile carefully and may want to consider alternative investment options in the pharmaceutical sector.



You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.